|
Abdullaev Sh.P., Shatokhin M.N., Tuchkova S.N., Abdullaev Sh.P., Teodorovich O.V., Loran O.B., Sychev D.A.
Study of allelic variants of the CYP2D6 and CYP3A genes on the effectiveness and safety of tamsulosin therapy in patients with BPH: results of a pilot study
|
№6 / 2023
|
|
A.V. Govorov, A.L. Sarukhanian
Use of tamsulosin for a prevention of acute urinary retention in the perioperative period in patients undergoing to surgical procedures
|
№4 / 2023
|
|
S.P. Abdullaev, M.N. Shatokhin, O.V. Teodorovich, D.A. Sychev
Molecular genetic predictors of the efficacy and safety of tamsulosin therapy
|
№6 / 2022
|
|
A.G. Martov, A.S. Dukhanin, A.N. Bernikov
Current issues in alpha1-adrenergic blocker therapy: integration of pharmacological approach and clinical experience
|
№3 / 2022
|
|
D.V. Ergakov, A.G. Martov
New approaches to combined therapy of irritative symptoms in patients with benign prostatic hyperplasia
|
№2 / 2021
|
|
D.V. Ergakov, A.G. Martov
Paradigm shift in combination therapy during the COVID-19 pandemic
|
№1 / 2021
|
|
Z.K. Gadzhieva, M.A. Gazimiev, Yu.B. Kazilov, V.A. Grigoryan
The combined symptoms of male lower urinary tract: current treatment options
|
№4 / 2018
|
|
A.G. Martov, D.V. Ergakov, A.B. Novikov
Current prospects for improving the quality of life of patients with internal stents
|
№2 / 2018
|
|
L.G. Spivak, A.V. Mel'nikov
On prevention of post-surgery acute urinary retention
|
№6 / 2015
|
|
L.G. Spivak, K.L. Lokshin, A.Z. Vinarov
Review of Clinical Studies on Combination Therapy of 5α-Reductase Inhibitors and α1-Blockers in Patients with Benign Prostatic Hyperplasia
|
№4 / 2015
|
|
M.I. Davidov, K.L. Lokshin, I.S. Gorbunova
Incidence of acute urinary retention in patients with prostatic adenoma and 8-year long tamsulosin therapy
|
№2 / 2015
|
|
G.G. Krivoborodov, E.I. Tur
Long-term outcomes of the use of α-blockers tamsulosin in men with lower urinary tract symptoms and benign prostatic hyperplasia
|
№6 / 2014
|
Русский
